Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search:
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"CADTH Canadian Drug Expert Committee"
language:"English"
Showing
21
-
40
of
214
Search:
''
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
21
CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
22
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
23
CADTH Canadian Drug Expert Committee final recommendation: Sapropterin -- resubmission (Kuvan -- BioMarin Pharmaceuticals Canada Inc.) : indication: to reduce blood phenylalanine l...
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
24
CADTH Canadian Drug Expert Committee final recommendation: Selexipag (Uptravi -- Actelion Pharmaceuticals Canada Inc.) : Indication: pulmonary arterial hypertension
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
25
CADTH Canadian Drug Expert Committee recommendation: Brexpiprazole (Rexulti - Lundbeck Canada Inc and Otsuka Canada Pharmaceutical Inc.) : indication : treatment of schizophrenia i...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
26
CADTH Canadian Drug Expert Committee recommendation: Nitisinone (MDK-Nitisinone -- mendeliKABs inc.) : indication : the treatment of adult and pediatric patients with hereditary ty...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Read Now
27
CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension
Published 2018
Canadian Agency for Drugs and Technologies in Health
Read Now
28
CADTH Canadian Drug Expert Committee recommendation: Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasi...
Published 2018
CADTH
Read Now
29
CADTH Canadian Drug Expert Committee recommendation: Nitisinone (Orfadin -- Sobi Canada Inc.) : indication: the treatment of adult and pediatric patients with hereditary tyrosinemi...
Published 2018
CADTH
Read Now
30
CADTH Canadian Drug Expert Committee recommendation: Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease
Published 2018
CADTH
Read Now
31
CADTH Canadian Drug Expert Committee recommendation: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.) : indication : chronic hepatitis C virus infection
Published 2018
CADTH
Read Now
32
CADTH Canadian Drug Expert Committee recommendation: Travoprost 0.003% (Izba -- Novartis Pharmaceuticals Canada inc. on behalf of Alcon Canada Inc.) : indication : for the reductio...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
33
Optimal use of minimally invasive glaucoma surgery: Recommendations
Published 2019
Canadian Agency for Drugs and Technologies in Health
Read Now
34
CADTH Canadian Drug Expert Committee recommendation: Latanoprostene bunod (Vyzulta -- Bausch Health, Canada Inc.) : indication : for the reduction of intraocular pressure (IOP) in...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Read Now
35
CADTH Canadian Drug Expert Committee recommendation: Baricitinib (Olumiant -- Eli Lilly Canada Inc.) : indication : for use in combination with methotrexate (MTX) for the treatment...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Read Now
36
CADTH Canadian Drug Expert Review Committee final recommendation: Riociguat (Adempas - Bayer HealthCare Inc.) : indication: pulmonary arterial hypertension
Published 2015
Canadian Agency for Drugs and Technologies in Health
Read Now
37
CADTH Canadian Drug Expert Committee recommendation: Insulin glargine and lixisenatide (Soliqua -- Sanofi-Aventis Canada Inc.) : indication : adjunct to diet and exercise to improv...
Published 2019
CADTH
Read Now
38
CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) : indication : coronary artery disease with or without peripheral artery disease
Published 2018
CADTH
Read Now
39
CADTH Canadian Drug Expert Committee recommendation: Fluticasone Propionate (Aermony respiclick -- Teva Canada Innovation) : indication : maintenance treatment of asthma in patient...
Published 2018
CADTH
Read Now
40
Optimal use of minimally invasive glaucoma surgery: A health technology assessment : project protocol
Published 2018
CADTH
1
2
3
4
5
6
7
8
9
10
11
Back
Narrow Search
Remove Filters
Clear Filter
Author: CADTH Canadian Drug Expert Committee
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
610 - Medicine & health
201
330 - Economics
113
140 - Specific philosophical schools
24
700 - The arts; fine & decorative arts
17
580 - Plants (Botany)
3
800 - Literature & rhetoric
2
more ...
380 - Commerce, communications & transportation
1
see all ...
less ...
Language
English
Collection
National Center for Biotechnology Information
214
Author
CADTH Canadian Drug Expert Committee
Canadian Agency for Drugs and Technologies in Health
161
Recently Uploaded
Last Month
10
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?page=2&filter%5B%5D=author_facet%3A%22CADTH+Canadian+Drug+Expert+Committee%22&filter%5B%5D=language%3A%22English%22&type=AllFields
Send by Email
×
Loading...